KRAS and colorectal carcinoma: Through in-depth analysis and interpretation of these studies, the following conclusions can be drawn: (1) PCK1 was previously reported to be upregulated in KRAS-mutated CRC, and PCK1 is highly expressed in CRCs with P53 mutations.